Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor

Rhea-AI Summary

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) has appointed Shadow Lake Group as its Business Development advisor to further its strategic partnerships and commercialization efforts. The collaboration aims to leverage SLG's expertise in neuroscience and oncology, enhancing Bioasis' proprietary xB3™ platform technology aimed at treating CNS disorders. Executive Chair Deborah Rathjen expressed optimism about this engagement, highlighting the potential for significant advancements in the company's scientific and business initiatives.

Positive

• Engagement with Shadow Lake Group to enhance business development.
• Expected growth in strategic partnerships leveraging SLG's expertise.
• Increased focus on commercialization of the xB3™ platform technology.

Negative

• None.

NEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB³™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Shadow Lake Group Inc. and its affiliate SLG Europe BV (“SLG”) as Business Development advisor.

“We are delighted to engage with Shadow Lake Group to expand our business development efforts,” said Deborah Rathjen, Ph.D., Bioasis’ Executive Chair. “The team at SLG will be able to leverage their previous knowledge of the xB³™ platform as well as their extensive transaction experience in neuroscience and oncology in the establishment of new and meaningful strategic partnerships for Bioasis.”

“The team at SLG is very excited to be working with Bioasis once again to support commercialization of this important and much needed BBB delivery platform,” said John Proffett, Managing Partner and Co-Founder of SLG. “We are impressed with the significant progress that the Bioasis team has made in both scientific and business development activities since our previous engagement, and we are looking forward to contributing to the future growth of the Company.”

On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chair of the Board

Follow on:
Facebook
Instagram
LinkedIn
Twitter

BTI-CRP

About Bioasis
Bioasis Technologies Inc.is a biopharmaceutical company developing the xB³™ platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood-brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit www.bioasis.us.

About Shadow Lake Group Inc.
Shadow Lake Group and its affiliate SLG Europe BV (SLG) is a boutique life sciences transaction advisory firm with a global focus. SLG works with both private and public companies in all therapeutic areas and stages of development to help them achieve their business goals. SLG has offices in Toronto, Canada, Boca Raton, Florida, and Amsterdam, the Netherlands.
http://shadowlakegroup.com/

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, along with other statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: Bioasis Technologies Inc.

Contacts:

Deborah Rathjen, Ph.D., Executive Chair of the Board and CEO
deborah@bioasis.us
203-533-7082

Investor Contact:
Graeme Dick
Colwell Capital Corp.
graeme@colwellcapital.com
403-561-8989 

FAQ

What is the significance of Bioasis appointing Shadow Lake Group as a Business Development advisor?

The appointment aims to enhance Bioasis's business development efforts and establish strategic partnerships to commercialize its xB3™ platform technology.

How could the partnership with Shadow Lake Group impact Bioasis (BIOAF)?

The partnership could lead to increased strategic partnerships and commercialization opportunities for Bioasis, potentially accelerating growth in the CNS treatment market.

What is the focus of Bioasis Technologies' xB3™ platform technology?

The xB3™ platform technology focuses on delivering therapeutics across the blood-brain barrier to treat CNS disorders, including brain cancers and neurodegenerative diseases.

Who is Deborah Rathjen in relation to Bioasis?

Deborah Rathjen is the Executive Chair of Bioasis Technologies Inc., and she has emphasized the importance of the partnership with Shadow Lake Group.